厦门大学学报:哲学社会科学版
廈門大學學報:哲學社會科學版
하문대학학보:철학사회과학판
Journal of Xiamen University(A Quarterly for Studies in Arts & Social Sciences)
2014年
4期
34~44
,共null页
市场势力估计 勒纳指数 KBL模型 化学药品制剂企业
市場勢力估計 勒納指數 KBL模型 化學藥品製劑企業
시장세력고계 륵납지수 KBL모형 화학약품제제기업
market power estimation;Lemer index;KBL model;chemical drug companies
市场势力的估计长期困扰着产业组织领域的研究。以中国化学药品制剂企业为例,基于KBL模型对企业市场势力及其影响因素的研究发现:第一,中国化学药品制剂企业的勒纳指数略高于0.3,意味着企业拥有市场势力,这是导致中国药品价格高企的一个重要原因;第二,广告支出强度大、创新能力强的大型制药企业有更高的市场势力。该研究结果为中国医药价格管制政策的制定提供了经验证据:一方面,从动态的角度来看,政府应健全创新支持体系,创造条件推动内资企业、中小型企业、出口型企业通过加强创新而提高竞争力,以长期促进社会福利的改善;另一方面,市场势力的存在推高了当前的药品价格,应重点对大型制药企业与公立医院之间可能存在的合谋行为进行管制。
市場勢力的估計長期睏擾著產業組織領域的研究。以中國化學藥品製劑企業為例,基于KBL模型對企業市場勢力及其影響因素的研究髮現:第一,中國化學藥品製劑企業的勒納指數略高于0.3,意味著企業擁有市場勢力,這是導緻中國藥品價格高企的一箇重要原因;第二,廣告支齣彊度大、創新能力彊的大型製藥企業有更高的市場勢力。該研究結果為中國醫藥價格管製政策的製定提供瞭經驗證據:一方麵,從動態的角度來看,政府應健全創新支持體繫,創造條件推動內資企業、中小型企業、齣口型企業通過加彊創新而提高競爭力,以長期促進社會福利的改善;另一方麵,市場勢力的存在推高瞭噹前的藥品價格,應重點對大型製藥企業與公立醫院之間可能存在的閤謀行為進行管製。
시장세력적고계장기곤우착산업조직영역적연구。이중국화학약품제제기업위례,기우KBL모형대기업시장세력급기영향인소적연구발현:제일,중국화학약품제제기업적륵납지수략고우0.3,의미착기업옹유시장세력,저시도치중국약품개격고기적일개중요원인;제이,엄고지출강도대、창신능력강적대형제약기업유경고적시장세력。해연구결과위중국의약개격관제정책적제정제공료경험증거:일방면,종동태적각도래간,정부응건전창신지지체계,창조조건추동내자기업、중소형기업、출구형기업통과가강창신이제고경쟁력,이장기촉진사회복리적개선;령일방면,시장세력적존재추고료당전적약품개격,응중점대대형제약기업여공립의원지간가능존재적합모행위진행관제。
Market power estimation has long baffled researchers in the study of industrial organization. This paper uses the KBL model to estimate the market power and its determinants of China's chemical drug industry. The main conclusions are as follows : ( 1 ) The average Lerner index of the firms is slightly above 0.3, which means that the enterprises have significant market power, which, in turn, is one of the important causes behind high drug prices; (2) finns that are higher in advertising expenditure and more capable of innovation possess greater market power. Our results provide some empirical evidence for China's policy-making for medicine pricing. It is argued that, on the one hand, from a dynamic point of view, the government should build up an innovation-supporting system to promote and encourage domestic enterprises, small and medium-sized enterprises, and export-oriented enterprises to enhance their competitiveness by stepping up innovation thereby improving social welfare in the long term. On the other hand, since enterprises' market power pushes up drug prices, the government should focus on preventing and controlling possible collusions between public hospitals and large pharmaceutical companies.